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Identity 
Inheritance: Autosomal dominant; rare with unknown 
incidence. 
Clinics 
Phenotype and clinics 
- Major findings: Hypothalamic hamartoma: a non-
enhancing mass in the floor of the third ventricle 
posterior to the optic chiasm that is isointense to grey 
matter on T1 and T2 pulse sequences of an MRI, but 
may have distinct intensity on FLAIR. (Neither cranial 
CT examination nor cranial ultrasound examination is 
adequate for diagnosis of hypothalamic hamartoma). 
- Central polydactyly: The presence of six or more 
well-formed digits with a ‘Y’ shaped metacarpal or 
metatarsal bone. 
- Postaxial polydactyly: Can be either PAP-A with a 
well shaped digit on the ulnar or fibular aspect of the 
limb, or PAP-B with a rudimentary digit or nubin in the 
same position. 
- Bifid epiglottis: A midline anterior-posterior cleft of 
the epiglottis that involves at least two-thirds of the 
epiglottic leaf. It is a useful feature for clinical 
diagnosis because it appears to be very rare in 
syndromes other than PHS and is also rare as an 
isolated malformation. 
- Other: Imperforate anus, renal abnormalities 
including cystic malformations, renal hypoplasia, 
ectopic ureteral implantation, and pulmonary 
segmentation anomalies such as bilateral bilobed lungs. 
Neoplastic risk 
No increased risk of cancer has been reported for 
individuals with PHS. Hypothalamic hamartomas, a 
benign growth, are found in a majority of patients. 
Treatment 
Treatment of individuals with PHS depends on their 
individual manifestations. Management of epiglottic 
abnormalities depends on the type of abnormality and 
extent of respiratory compromise. Seizures are treated 
symptomatically. Treatment for endocrine 
abnormalities, especially for cortisol deficiency, is
urgent. Repair of polydactyly can be undertaken on an 
elective basis and anal atresia or stenosis treated in the 
standard manner. Hypothalamic hamartomas should not 
be removed or biopsied because of the risk of surgical 
complications and need for hormone supplements 
during the individual's remaining life. 
Prognosis 
The prognosis for an individual with PHS and no 
known family history of PHS is based on the 
malformations present in the individual. Literature 
surveys are not useful for this purpose because reported 
cases tend to show bias of ascertainment to more severe 
involvement. Although PHS has been categorized as a 
member of the CAVE (cerebro-acro-visceral early 
lethality) group of disorders, few affected individuals 
have an early lethality phenotype. This early lethality is 
most likely attributable to panhypopituitarism that is 
caused by pituitary or hypothalamic dysplasia or sever  
airway malformations such as laryngotracheal clefts. In 
addition, imperforate anus can cause serious 
complications if not recognized promptly. Thus, in the 
absence of life-threatening malformations, the 
prognosis should be assumed to be excellent for 
individuals with the nonfamilial occurrence of PHS. 
For individuals with a family history of affected family 
members, the prognosis is based on the degree of 
severity present in the family. Several large families 
have been reported as having a mild form of PHS with
excellent general health and normal longevity. 
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A : MRI showing hypothalamic hamartoma in PHS patient. 
B : Hand film showing central polydactyly, note ‘Y’ shaped metarcarpal. 
 
 




Description: GLI3 has 15 exons, 14 of which are 
coding exons, and extends over approximately 300 kb 
of genomic DNA. 
Protein 
Description: 1580 amino acids; GLI3 contains a C2H2 
zinc finger and six additional domains conserved 
between GLI family members. 
Function:  GLI3 functions as both an activator and 
repressor of transcription, playing a central role in the 
Sonic Hedgehog pathway. In the presence of Sonic 
Hedgehog GLI3 enters the nucleus and activates 
transcription of downstream genes. In the absence of  
Sonic Hedgehog full length GLI3 is retained in the 
cytoplasm where it is cleaved into a repressor form. 
The repressor form is free to move into the nucleus and 
downregulate transcription. 
Homology: GLI family of transcription factors, C2H2 
zinc finger domain. 
Mutations 
Germinal: Over 36 mutations have been identified in 
individuals with PHS. All mutations identified to date 
predict a truncated protein. 
Mutations that cause PHS are thought to result in the 
production of a constituitive repressor protein. The 
majority of truncating mutations in the middle third of 
the protein cause PHS. These mutations retain the 







Schematic of GLI3 protein showing seven conserved domains between the GLI family members, the C2H2 zinc finger is shown in red. 
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